Brokerages Set Bruker Co. (NASDAQ:BRKR) PT at $70.50

Shares of Bruker Co. (NASDAQ:BRKR - Get Free Report) have received an average rating of "Moderate Buy" from the eleven analysts that are covering the firm, MarketBeat Ratings reports. Five research analysts have rated the stock with a hold recommendation and six have given a buy recommendation to the company. The average 1 year price objective among brokers that have issued ratings on the stock in the last year is $70.50.

A number of brokerages have weighed in on BRKR. Stifel Nicolaus cut their price target on shares of Bruker from $70.00 to $57.00 and set a "hold" rating on the stock in a research note on Friday, February 14th. UBS Group assumed coverage on shares of Bruker in a research report on Tuesday, December 10th. They issued a "neutral" rating and a $66.00 price objective on the stock. Bank of America upped their target price on shares of Bruker from $78.00 to $80.00 and gave the stock a "buy" rating in a research note on Friday, December 13th. Wells Fargo & Company dropped their price target on Bruker from $78.00 to $75.00 and set an "overweight" rating on the stock in a research note on Wednesday, November 6th. Finally, Citigroup reduced their price objective on Bruker from $80.00 to $75.00 and set a "buy" rating for the company in a research report on Wednesday, November 6th.

Institutional Investors Weigh In On Bruker

A number of institutional investors and hedge funds have recently made changes to their positions in BRKR. Gordian Capital Singapore Pte Ltd acquired a new position in Bruker during the fourth quarter worth $234,000. EDENTREE ASSET MANAGEMENT Ltd grew its position in shares of Bruker by 11.2% in the 4th quarter. EDENTREE ASSET MANAGEMENT Ltd now owns 158,000 shares of the medical research company's stock valued at $9,262,000 after acquiring an additional 15,900 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its stake in shares of Bruker by 17.1% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 356,969 shares of the medical research company's stock worth $20,926,000 after purchasing an additional 52,214 shares during the last quarter. Voloridge Investment Management LLC raised its holdings in shares of Bruker by 179.6% in the 4th quarter. Voloridge Investment Management LLC now owns 18,906 shares of the medical research company's stock valued at $1,108,000 after purchasing an additional 12,145 shares during the period. Finally, Two Sigma Advisers LP lifted its stake in Bruker by 406.1% in the 4th quarter. Two Sigma Advisers LP now owns 140,700 shares of the medical research company's stock valued at $8,248,000 after purchasing an additional 112,900 shares during the last quarter. Institutional investors own 79.52% of the company's stock.

Bruker Trading Up 1.5 %

NASDAQ:BRKR traded up $0.79 during mid-day trading on Friday, hitting $51.54. The company had a trading volume of 1,115,898 shares, compared to its average volume of 1,599,775. The firm has a market cap of $7.81 billion, a P/E ratio of 67.81, a P/E/G ratio of 3.46 and a beta of 1.16. The business's fifty day moving average is $57.14 and its two-hundred day moving average is $60.24. The company has a debt-to-equity ratio of 1.15, a quick ratio of 0.77 and a current ratio of 1.60. Bruker has a fifty-two week low of $48.07 and a fifty-two week high of $94.86.

Bruker (NASDAQ:BRKR - Get Free Report) last issued its earnings results on Thursday, February 13th. The medical research company reported $0.76 EPS for the quarter, beating the consensus estimate of $0.75 by $0.01. Bruker had a net margin of 3.36% and a return on equity of 21.01%. As a group, research analysts expect that Bruker will post 2.69 earnings per share for the current year.

About Bruker

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.